BetaBASE is a bioresorbable bone replacement from microporous and macroporous β-tricalcium phosphate. BetaBASE consists of pure-phase β-TCP.
Potential risks of infection involved in the use or processing of biological material (HIV, BSE, inter alia) are non-existent with BetaBASE.
BetaBASE has an interconnected pore system with micropores and macropores that reproduce the well-known osteoconductive effect almost perfectly.
Osteoblasts and blood vessels are able to proliferate rapidly in the open pore system and grow swiftly in the BetaBASE. This also enables internal resorption of the materials.
The high overall porosity of BetaBASE (> 60 %) means that the body has to break down a far smaller quantity of bone replacement material, based on the volume of the defect. This accelerates the resorption process and also creates new opportunities to fill large bone defects. Clinical studies have demonstrated that the material is completely resorbable after 9 to 12 months.
The polyhedric granular structure of Betabase makes it safe and easy to apply to the defect, in particular when mixed with the patient’s blood.
BetaBASE conforms to ASTM F 1088-04, the internationally recognised standard for materials.
Indications
Addition of the material to autogenic or allogenic spongiosa to reconstruct bone defects e.g. in cases of spondylodesis, vertebral body replacement and in joint replacement surgery.
Filling defects in correction osteotomies
Filling the sites from which autogenic bones have been removed
Filling bone cysts
Use in arthrodesis
Filling defects after the removal of benign bone tumours
Application
It is advisable to apply Betabase in a moist state.